Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa

International Journal of Hematology

Volumn 95, Issue 2, 2012, Pages 209-213

  Itonaga, Hidehiro ^a   Tsushima, Hideki ^b   Hata, Tomoko ^b   Matsuo, Emi ^c   Imanishi, Daisuke ^b   Imaizumi, Yoshitaka ^b   Kawaguchi, Yasuhisa ^d   Fukushima, Takuya ^b   Doi, Yuko ^a   Mori, Sayaka ^a   Kamihira, Shimeru ^a   Tomonaga, Masao ^e   Miyazaki, Yasushi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^d Nagasaki Municipal Medical Center   (Japan)

^e Japanese Red Cross Nagasaki Atomic Bomb Hospital Nagasaki   (Japan)

Author keywords

Chronic myelogenous leukemia; Imatinib; Interferon; T315I

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; BCR ABL GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CASE REPORT; CHROMOSOME ABERRATION; CHROMOSOME G BAND; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CYTOGENETICS; DISEASE COURSE; DRUG DOSE REDUCTION; GENE MUTATION; GENE SEQUENCE; HIGH RISK PATIENT; HUMAN; MALE; MUSCLE CRAMP; MUTATIONAL ANALYSIS; NEUTROPENIA; ONCOGENE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; DRUG COMBINATION; GENETICS; MIDDLE AGED; POINT MUTATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; POINT MUTATION; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84862656602     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1005-1     Document Type: Article

References (25)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999; 340:1330-40. (Pubitemid 29196596)
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervanteset F, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. (Pubitemid 36302244)
3. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355: 2408-17. (Pubitemid 44903745)
4. Silver RT, Talpaz M, Sawyers CL, Drucker BJ, Hochhaus A, Schiffer CA, et al. Four years of follow-up of 1027 patients with late chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood. 2004;104:11a (abstract).
5. Saqlio G, Kim DW, Issaraqrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251-9.
6. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260-70.
7. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110:2242-9. (Pubitemid 47523141)
8. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12:7374-9. (Pubitemid 46095411)
9. Soverini S, lacobucci I, Baccarani M, Martinelli G. Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica. 2007;92:437-9. (Pubitemid 350144288)
10. Soverini S, Cloarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica. 2007;92:401-4. (Pubitemid 350143551)
11. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006;108:1421-3. (Pubitemid 44232047)
12. Velev N, Cortes J, Champlin R, Jones D, Rondon G, Giralt S, et al. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer. 2010;116:3631-7.
13. Nicolini FE, Basak GW, Soverini S, Martinelli G, Mauro MJ, Muller MC, et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011 (pii:2011-07-367326).
14. Nicolini FE, Mauro MJ, Martinelli G, Kim DW, Soverini S, Muller MC, et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(?) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood. 2009;114:5271-8.
15. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, et al. Simultaneous targeting of Aurora kinase and Bcr- Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood. 2008;111:4355-64.
16. Quintas-Cardama A, Kantarjian H, Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer. 2009;115:5382-93.
17. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia. 2003;17:2318-57. (Pubitemid 38072573)
18. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99:3472-5. (Pubitemid 34525335)
19. Polakova KM, Lopotova T, Klamova H, Moravcova J. Highresolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain. Leuk Res. 2008;38:1236-43.
20. Yin CC, Cortes J, Galbincea J, Reddy N, Breeden M, Jabbour E, et al. Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Sci. 2010;101:2005-10.
21. ChanWW, Wise SC, KaufmanMD, Ahn YM, Ensinger CL, Haack T, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 2011;19:556-68.
22. Cheetham GM, Charlton PA, Golec JM, Pollard JR. Structural basis for potent inhibition of the Aurora kinase and a T315I multi-drug resistant mutant from Abl kinase by VX-680. Cancer Lett. 2007;251:323-9. (Pubitemid 46669805)
23. Crespan E, Radi M, Zanoli S, Schenone S, Botta M, Maga G. Dual Src and Abl inhibitors target wild type Abl and the AblT315I imatinib-resistant mutant with different mechanisms. Bioorg Med Chem. 2010;18:3999-4008.
24. Sillaber C, Mayerhofer M, Bohm A, Vales A, Gruze A, Aichberger KJ, et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest. 2008;38:43-52. (Pubitemid 350293855)
25. de Lavallade H, Khorashad JS, Davis HP, Milojkovic D, Kaeda JS, Goldman JM, et al. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood. 2007;110: 2779-80. (Pubitemid 47523217)